May MT, Vehreschild JJ, Trickey A, Obel N, Reiss P, Bonnet F, Mary-Krause M, Samji H, Cavassini M, Gill MJ, Shepherd LC, Crane HM, D'Arminio Monforte A, Burkholder GA, Johnson MM, Sobrino-Vegas P, Domingo P, Zangerle R, Justice AC, Sterling TR, Miró JM, Sterne JAC, Boulle A, Stephan C, Miro JM, Cavassini M, Chêne G, Costagliola D, Dabis F, Monforte AD, Del Amo J, Van Sighem A, Fätkenheuer G, Gill J, Guest J, Haerry DH, Hogg R, Justice A, Shepherd L, Obel N, Crane H, Smith C, Reiss P, Saag M, Sterling T, Teira R, Williams M, Zangerle R, Sterne J, May M, Ingle S, Trickey A. Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 Jun 15;62(62). 1571-1577. PMID: 27025828 [PubMed] PMCID: PMC4885653
CD4 count at start of combination antiretroviral therapy (ART) is strongly associated with short-term survival, but its association with longer-term survival is less well characterized.